Getting a Clear View: Lessons From The CLARITY-BPA Study

July 17, 2019
1:00 pm US Eastern Time

Slides & Resources


Laura Vandenberg: Getting a Clear View: Lessons from the CLARITY-BPA Study


Prins, G., Patisaul, H., Belcher, S., Vandenberg, L. 2018. CLARITY‐BPA academic laboratory studies identify consistent low‐dose Bisphenol A effects on multiple organ systems. Basic Clin Pharmacol Toxicol. 201 8;1-18.DOI: 10.1111/bcpt.13125.

Vandenberg, L., Hunt, P., and Gore, A. 2019. Endocrine disruptors and the future of toxicology testing — lessons from CLARITY–BPA. Nature Reviews Endocrinology 15, 366–374. 



Bisphenol A (BPA) is produced in high volume and is still in use in a variety of products globally. Many independent, academic studies have demonstrated an association between exposure to BPA and multiple adverse health outcomes including endocrine-disrupting end-points. However, studies included in regulatory risk assessments have been cited as evidence that current uses of BPA are safe. The U.S. National Institute of Environmental Health Sciences (NIEHS), the National Toxicology Program (NTP), and the Food and Drug Administration (FDA) sought to address these disparities in scientific findings and put together the Consortium Linking Academic and Regulatory Insights on BPA Toxicity, otherwise known as CLARITY-BPA.

The CLARITY-BPA study promised to help scientists, regulators, and other decision-makers to understand why some studies suggest that BPA can cause harm, while others do not. Did it meet this promise? In this webinar, the study design and approach was presented, and some compelling conclusions from the data that are available so far were discussed.

Dr. Laura Vandenberg is an Associate Professor and Graduate Program Director in the Department of Environmental Health Sciences in the University of Massachusetts Amherst School of Public Health and Health Sciences. Trained as a developmental biologist and endocrinologist, Dr. Vandenberg’s laboratory research focuses on how low level exposures to endocrine disrupting chemicals, and in particular compounds that mimic estrogens, can induce diseases. She is especially interested in the effects of estrogenic compounds on breast cancer and works to determine when individuals are most susceptible to these exposures. Outside of the lab, her research critically evaluates issues that affect risk and hazard assessments for endocrine disrupting chemicals including low dose effects, non-monotonic dose responses, critical windows of susceptibility, routes of exposure, and testing methods. Dr. Vandenberg is an author on more than 85 peer reviewed papers and ten book chapters. She has served on a number of US and international expert panels to assess endocrine disrupting chemicals and is regularly asked to speak at conferences around the world.

This webinar is one in a monthly series sponsored by the Collaborative on Health and the Environment’s EDC Strategies Partnership. The CHE EDC Strategies Partnership is chaired by Carol Kwiatkowski and Katie Pelch (TEDX), Sharyle Patton (Commonweal Biomonitoring Resource Center), Jerry Heindel (Commonweal's HEEDS), and Genon Jensen (HEAL) and coordinated by Hannah Donart (Collaborative on Health and the Environment, a Commonweal program). To see a full list of past calls and webinars related to EDCs and listen to or view recordings, please visit our partnership page.

This webinar was moderated by Jerry Heindel, PhD, founder and director of Commonweal's Healthy Environment and Endocrine Disruptor Strategies (HEEDS). It lasted for 30 minutes and was recorded for our call and webinar archive.